News & Media

News and Media

Our News

HTL at Bio International 2021

June 9, 2021

HTL is thrilled to participate to Bio International 2021, the world’s largest business convention dedicated to biotech and pharma. Together with Business France and French Healthcare, we will be next week on the One-on-One partnering platform. We are looking forward to identifying and developing new partnerships!

New offices in New Jersey, USA and Singapore

June 8, 2021

HTL is pleased to announce the opening of our new offices in New Jersey, USA and Singapore. This announcement is a natural progression of our continued expansion in North America and Asia. The new offices will allow us to serve our global clientele and partners more effectively and efficiently. Our products are used by market leaders worldwide, and we are continuously creating global and local partnerships with major research players. This is yet another milestone in our journey towards the next breakthrough in human health.

For more information, give us a call or use our contact form.

EcoVadis Sustainability rating: HTL receives Gold Medal

June 4, 2021

HTL has obtained a gold medal for its first EcoVadis sustainability rating. This places us in the top 5% of companies evaluated in our industry sector. We would like to thank all the employees who are making this success possible and work on improving our environmental, social and societal impacts. This achievement encourages us to continue measure and improve our CSR performance. Let’s go beyond, together!

Click here to view the certificate.

PRESS RELEASE: HTL Biotechnology and Terasaki Institute for Biomedical Innovation announce Memorandum of Understanding for research in translational biomaterials

May 10, 2021

HTL, the world leader in biotechnology solutions based on hyaluronic acid (HA) and other biopolymers and the Terasaki Institute for Biomedical Innovation (TIBI), a US-based research institute at the frontier of personalized and precision medicine, announced their Memorandum of Understanding (MOU) to explore the creation of a joint research program. This program will focus on biomaterials for translational programs combining TIBI’s microneedle and bioprinting technologies with HTL’s expertise in biopolymers for aesthetics, dermatology, ophthalmology, rheumatology, tissue engineering and drug delivery applications.

Read more below.

English | Français

PRESS RELEASE: HTL and Echelon Biosciences Inc. announce strategic partnership to advance biopolymer platform and hyaluronic acid research tools

April 13, 2021

HTL, the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc., a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announce their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products.

The partnership provides academic research and pharmaceutical development laboratories expanded access to Good Manufacturing Practices (GMP)-grade, kit-packaged hyaluronic acid and glycosaminoglycan (GAG) products. By offering premium, clinical grade products to early-stage research investigators, the partnership seeks to bridge the gap between lab-based research, development and commercialization, and accelerate innovation worldwide.

Read more below.

English | Français | Deutsch

PRESS RELEASE: LabCom GELMECS, a new shared laboratory for biomaterials in regenerative medicine

December 10, 2020

HTL is engaged in the development of biomaterials for regenerative medicine by the creation of a shared laboratory with the RMeS (Regenerative Medicine and Skeleton) research unit: the GELMECS LabCom, based in Nantes, France. Its objective is to develop hydrogels for the pharmaceutical industry, tissue engineering and assisted cell therapy. These new biomaterials using silanized hyaluronic acid have demonstrated their pertinence in terms of interest and efficiency for the creation of injectable bone replacements and cement foams for bone regeneration.

Read more below.

English | Français

HTL sponsors the 11th World Biomaterials Congress - WBC 2020

December 2, 2020

HTL is proud to sponsor WBC 2020 virtual, the 11th World Biomaterials Congress that will take place online from 11 to 15 December. This event connects an international audience of thousands of biomaterials professionals: researchers, academics, scientists and other representatives from biomedical companies.

We are happy to highlight our Scientific Advisor Glenn Prestwich, who will be a keynote speaker at the Special Symposium « Hyaluronic Acid, a powerful biomedical tool » on December 12th. He will be discussing chemically modified Hyaluronic Acid for regenerative and reparative medicine.

HTL will also be a virtual exhibitor at WBC, with the objective of developing and strengthening its academic partnerships. More information at

Lockdown: you can count on us

November 1, 2020

Following the latest lockdown measures announced in different parts of the world, HTL would like to confirm that we are able to continue to deliver our products as usual and ensure our customer service. Do not hesitate to contact us. Together, we will continue to work for health and well-being.

With the evolving health situation, our responsibility is to maintain continued vigilance. The health and safety of our employees and our community remains our priority. We continue to rigorously apply our enhanced protection system: spreading prevention measures, reorganized workstations, priority for teleworking, cancellation of all trips and visits, reinforced cleaning.

Together, let's stay mobilized.

Meet HTL at CPhI Festival of Pharma 2020 from 12 to 16 October

October 5, 2020

As CPhI Worldwide 2020 will take place online for the first time, the HTL team will be ready to join the global pharma industry and network online at the Festival of Pharma from 12 to 16 October. Our team will discuss business and innovation opportunities around biopolymer APIs and raw materials. Together, we continue to develop the potential of biopolymers of non-animal origin: Hyaluronic Acid, Heparosan, Chondroitin and more. Join us and achieve your business goals. Let’s stay connected! Click here to sign up for free

COVID-19: HTL is protecting the safety of its employees and its facility

March 20, 2020

HTL is protecting the safety of its employees and its facility, in order to guarantee supply chain continuity for its clients. Click here to view the statement. Cliquez ici pour visualiser le point de situation.

We will update this status report as the situation develops. The HTL team is available to answer your questions or provide further information.